Regeneron Pharmaceuticals' Other Working Capital Changes rose 119.01% to $47.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $513.4 million, marking a year-over-year increase of 173.23%. This contributed to the annual value of $407.5 million for FY2024, which is 239.30% up from last year.
As of FY2024, Regeneron Pharmaceuticals' Other Working Capital Changes stood at $407.5 million, which was up 239.30% from $120.1 million recorded in FY2023.
In the past 5 years, Regeneron Pharmaceuticals' Other Working Capital Changes ranged from a high of $407.5 million in FY2024 and a low of $120.1 million during FY2023.
Its 3-year average for Other Working Capital Changes is $225.4 million, with a median of $148.6 million in 2022.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Other Working Capital Changes slumped by 38.26% in 2022, and later spiked by 239.30% in 2024.
Over the past 5 years, Regeneron Pharmaceuticals' Other Working Capital Changes (Yearly) stood at $148.1 million in 2020, then surged by 62.53% to $240.7 million in 2021, then slumped by 38.26% to $148.6 million in 2022, then fell by 19.18% to $120.1 million in 2023, then surged by 239.30% to $407.5 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value